RNS Number:8867W
Schering AG
8 January 2001



Schering: Climodien(R) granted approval in the Netherlands

Berlin, Germany, January 8, 2001; Schering AG (NYSE: SHR) announced today that
the Netherlands health authority granted approval for Climodien(R) in December
2000. Climodien(R) is a novel continuous combined, hormonal replacement therapy
product aims to stop blood flow. It contains the progestin Dienogest with
antiandrogenic activity, and estradiol valerate. It is used for treatment of
climacteric symptoms.

When taking Climodien(R), a continuous combined regimen product, the regular
withdrawal bleeding, that occurs during so called sequential or cyclic HRT
treatment, can be prevented. This means a big advantage for women. Climodien(R)
treats menopausal complaints due to estrogen deficiency.

"With this decision, conditions for registration of Climodien(R) in the EU are
fulfilled. Schering will initiate mutual recognition in the other EU member
states. Approval of Climodien(R) from health authorities within the EU is
expected during the course of this year," said Dr. Giuseppe Vita, Chairman of
the Board of Executive Directors of Schering AG.

Schering AG is a research-based pharmaceutical company. Its activities are
focused on four business areas: fertility control and hormone therapy,
diagnostics and radio pharmaceuticals, dermatology as well as therapeutics for
disabling diseases, e.g. multiple sclerosis, leukemia and solid tumors. As a
global player with innovative products Schering AG aims for leading positions in
specialized markets worldwide. With in-house R&D and supported by an excellent
global network with external partners, Schering AG is securing a promising
product pipeline. Using new ideas, Schering AG aims to make a recognized
contribution to medical progress and strives to improve the quality of life.

An electronic version of this news release - as well as additional information
about Schering AG - is available at www.schering.de.

Berlin, Germany, January 8, 2001

Schering AG
Corporate Communication

For further information please contact:

* Dr. Friedrich von Heyl - Business and Financial Communication: 
  Tel.: +49-30-468 152 96; 
  Fax:  +49-30-468 166 46; 
  eMail: friedrich.vonheyl@schering.de

* Dr. Monika Klutz-Specht - Pharma Communication: 
  Tel.: +49-30-468 154 35;
  Fax:  +49-30-468 167 10; 
  eMail: monika.klutzspecht@schering.de

* Peter Vogt - Investor Relations: 
  Tel.: +49-30-468 128 38; 
  Fax:  +49-30-468 166 46; 
  eMail: peter.vogt@schering.de



Certain statements in this press release that are neither reported financial
results nor other historical information are forward-looking statements,
including but not limited to, statements that are predictions of or indicate
future events, trends, plans or objectives.  Undue reliance should not be
placed on such statements because, by their nature, they are subject to 
known and unknown risks and uncertainties and can be affected by other 
factors that could cause actual results and Schering AG's plans and objectives
to differ materially from those expressed or implied in the forward-looking
statements.  Certain factors that may cause such differences are discussed
in our Form 20-F registration statement.  Schering AG undertakes no obligation
to update publicly or revise any of these forward-looking statements, whether
to reflect new information or future events or circumstances or otherwise.